Australian health stocks drop most in 4 months; CSL falls after drug trial fails

ResMed

12/02/2024 24:04

** Aussie healthcare stocks  .AXHJ  fall as much as 4.2%,
their biggest decline since Oct 12, if trend holds
    ** The sub-index hits lowest level since Jan 25
    ** Biotechnology co CSL slumps 4.4%, and is the top loser on
ASX 200  .AXJO  after a failed phase 3 AEGIS-II trial for
evaluating the efficacy and safety of their drug CSL112 
    ** ASX-listed shares of medical device maker Resmed  RMD.AX 
drop 1.1%
    ** Cochlear  COH.AX  and Ramsay Healthcare  RHC.AX  shed
0.4% and 0.5%, respectively
    ** Sub-index has risen 5.6% this year as of last close


 (Reporting by Poonam Behura in Bengaluru)
 ((Poonam.Behura@thomsonreuters.com;))